External validation of a microRNA thyroid classifier: a real-world prospective study
Authors' conclusion
The mir-THYpe full molecular test supported 95.5% of clinical decisions when negative and 89.8% when positive, reducing surgery rates by 79.5%. Therefore, the integration of this microRNA-based classifier into clinical practice represents a valuable tool in managing indeterminate thyroid nodules, reducing unnecessary thyroidectomies, and conserving valuable healthcare resources.
Study context
- Population
- Patients with indeterminate thyroid nodules (Bethesda III/IV) on fine-needle aspiration biopsy (FNAB) cytologyanalysed
- Participants
- 256 patients
- Outcome
- Real-world clinical utility and diagnostic performance of the microRNA-based molecular test
Methodological detailsexternal, independent, prospective, real-world, observational, non-interventional
- External
- Independent
- Prospective
- Real-world
- Observational
- Non-interventional
Performance
As reported in the abstract
Diagnostic performance of the miRNA test in Bethesda III/IV nodules
Sensitivity
83.0%
Specificity
83.5%
PPV
62.8%
NPV
93.6%
Further findings
Surgery by test result
- Test positive for malignancy
- 90 patients
- Test-positive who underwent surgery
- 79 (90%)
- Test-negative nodules
- 158
- Test-negative who underwent thyroidectomy
- 7 (4.4%)
Original publication
External validation of a microRNA thyroid classifier: a real-world prospective study. Eur Thyroid J. Published 8 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →